


Curriculum Vitae

Name	Prof. Dr. med. Arndt VOGEL	
Current Position & Affiliation	Senior consultant Clinic for Gastroenterology, Hepatology and Endocrinology Head of the GI-Cancer Center at Medical School Hannover	
Country	Germany	
Educational Background		

April 1991 – Nov. 1997:	Medical School Georg-August University Göttingen
April 1998 – Dez. 1999	Internship, Dept. of Gastroenterology and Hepatology, ZKH Bremen-Mitte, Bremen,
Jan. 2000 – April 2002	Residency, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover
Since Nov. 2004	Residency, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover
Feb. 2008	Board certification for Internal Medicine
Juni 2010	Board certification for Internal Medicine – Gastroenterology
Since Oct. 2011	Senior consultant for Gastroenterology and Hepatology
Juni 2012	Professorship for Gastrointestinal Oncology, MHH
Since March 2017	Head of the Gastrointestinal Cancer Center, MHH, Hannover

Professional Experience

Mai 2002 - Okt. 2004	Postdoctoral Fellow (sponsored by the German Research Fund), Oregon Health and Science University, Portland, Oregon postdoctoral advisor: Markus Grompe
Since Nov. 2004	Independent Investigator in Oncology, MHH

Professional Organizations

Arbeitsgemeinschaft Internistische Onkologie, American Society of Clinical Oncology, Deutsche Gesellschaft für Innere Medizin, Deutsche Krebshilfe, Deutsche Gesellschaft für Gastrointestinale Erkrankungen, European Society for Medical Oncology, European Association for the Study of the Liver

Main Scientific Publications

- 1) **A Vogel**, S Qin, M Kudo Y, S Stacie, H Tatsuya, JH Yoon, L Fartoux, K Simon, C López, M Sung, K Mody, T Otsuka, T Tamai, L Bennett, G Meier, V Breder. Patient-reported Outcomes From a Phase III Randomized Open-Label Trial of Lenvatinib Versus Sorafenib for First-line Treatment of Unresectable Hepatocellular Carcinoma
Lancet Gastroenterology and Hepatology. 2021, online ahead of print, IF,18,5
- 2) **A Vogel** and E. Martinelli
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.
Annals of Oncology. 2021, in press IF 18,27
- 3) D Pfister, N Gonzalo Núñez, O Govaere, A Sinha, M Pinter, M Szydłowska, E Friebel, A Deczkowska, A Weiner, T Engleitner, R Pinyol, D Lenggenhager...MM. Kirstein, **A. Vogel**.... A Weber, F Meissner, I Amit, B Becher, JM Llovet, M Heikenwalder.
PD-1-targeted immunotherapy in NASH-induced liver cancer induces a pro-tumorigenic environment through CD8+PD-1+ T-cells
Nature. 2021, in press IF 42,79
- 4) G Kendre, S Marhenke, G Lorz, D Becker, T Reineke-Plaaß, T Poth, K Murugesan, F Kühnel, N Woller, RM Wirtz, A Pich, JU Marquardt, M Saborowski, **A Vogel***, and **A Saborowski***. * contributed equally.
The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
Hepatology. 2021, in press. IF 14,68
- 5) **A Vogel**, L Rimassa, HC Sun, GK Abou-Alfa, A El-Khoueiry, DJ Pinato, J Sanchez Alvarez, M Daigl, P Orfanos, M Leibfried, MH Blanchet Zumofen, VE Gaillard and P Merle.
Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: A network meta-analysis.

Liver Cancer. 2021, in press. IF 9,72

- 6) Buitrago-Molina LE, Marhenke S, Becker D, Geffers R, Itzel T, Teufel A, Jaeschke H, Lechel A, Unger K, Markovic J, Sharma AD, Marquardt JU, Saborowski M, Saborowski A, **Vogel A**
p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model.
Cellular and Molecular Gastroenterology and Hepatology. 2021, in press. IF 7,07
- 7) Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
JHEP Reports. 2020, 13;3(2):100215
- 8) Welland S, De Castro T, Wirth T, Kleine M, Ringe KI, Saborowski A and **Vogel A.**
Best supportive care in a young patient with locally advanced MSI-high colon cancer?
Zeitschrift für Gastroenterologie. 2020, ;58(9):872-876.
- 9) Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, **Vogel A.**
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncology 2020 IF: 35,38
- 10) Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Cheville JC, Mazza G, Hirschfield GM, Ponsioen CY, Bergquist A, Milkiewicz P, Lazaridis KN, Schramm C, Manns MP, Färkkilä M, **Vogel A**; International PSC study group, Boberg KM, Schirmacher P, Karlsen TH
Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities.
Hepatology. 2020, in press. IF: 14,07
- 11) Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, **Vogel A**, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY.
-

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. **Annals of Oncology**. 2020; 31(3):334-351. IF: 13,93

- 12) A Alsina, M Kudo, **A Vogel**, AL Cheng, WY Tak, BY Ryoo, TRJ Evans, C López López, B Daniele, S Misir, M Ren, N Izumi, S Qin and RS Finn
Effects of Subsequent Systemic Anticancer Medication Following First-line Lenvatinib: A Post Hoc Responder Analysis From the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
Liver Cancer. 2019; in press, IF: 5,94
- 13) Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, **Vogel A**, Johnson PJ
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.
Hepatology. 2019, in press, IF: 14.08
- 14) B Scheiner, M Kirstein, F Hucke, F Finkelmeier, K Schulze, J von Felden, S Koch, P Schwabl, J Hinrichs, F Waneck, O Waidmann, T Reiberger, C Müller, W Sieghart, M Trauner, A Weinmann, H Wege, J Trojan, M Peck-Radosavljevic, **A Vogel**, M Pinter
PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort.
Alimentary Pharmacology & Therapeutics 2019. IF: 7,35
- 15) A Saborowski K Wolff, S Spielberg, B Beer, B Hartleben, Z Erlangga, D Becker, LE Dow, S Marhenke, N Woller, K Unger, P Schirmacher, MP Manns, JU Marquardt, **A Vogel**, M Saborowski.
Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro.
Hepatology Communications. 2019, 5;3(3):423-436, IF: na
- 16) Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, **Vogel A**.
Second Line Chemotherapy in Biliary Tract Cancer: Outcome and Prognostic Factors.
Liver International. 2019 82, IF: 4,5
- 17) **A Vogel**, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, CJ Zech, D Arnold, E Martinelli; ESMO Guidelines Committee.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of Oncology. 2018 Oct 1;29: iv238-iv255, IF: 13,9

- 18) AX Zhu, RS Finn, J Edeline, S Cattani, S Ogasawara, D Palmer, C Verslype, V Zagonel, L Fartoux, **A Vogel**, D Sarker, G Verset, SL Chan, J Knox, B Daniele, AL Webber, SW Ebbinghaus, J Ma, AB Siegel, AL Cheng, M Kudo.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Lancet Oncology 2018, 19(7):940-952 IF: 36,42

- 19) M Kudo, R Finn, S Qin, KH Han, K Ikeda, F Piscaglia, A Baron, JW Park, G Han, J Jassem, JF Blanc, **A Vogel**, D Komov, TR Evans, C Lopez, C Dutcus, M Guo, K Saito, S Kraljevic, T Tamai, M Ren, AL Cheng.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Lancet 2018 24; 391:1163-1173; IF: 53,25

- 20) **A Vogel**, S Kasper, M Bitzer, A Block, M Sinn, H Schulze-Bergkamen, M Moehler, N Pfarr, V Endris, B Goepfert, K Merx, E Schnoy, JT Siveke, P Michl, D Waldschmidt, J Kuhlmann, M Geissler, C Kahl, R Evenkamp, T Schmidt, A Kuhlmann, W Weichert and S Kubicka.

PiCCA Study - Panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer - a randomized biomarker-driven clinical phase II AIO study.

European Journal of Cancer 2018, 92:11-19. IF: 7,19

- 21) Schweitzer N, Fischer M, Kirstein MM, Berhane S, Kottas M, Sinn M, Gonzalez-Carmona MA, Balta Z, Weismüller TJ, Strassburg CP, Reineke-Plaaß T, Bektas H, Manns MP, Johnson P, Weinmann A, **Vogel A**.

Risk estimation for biliary tract cancer: Development and validation of a prognostic score.

Liver International, 2017, 37(12):1852-1860. IF: 4,5

- 22) J Endig, LE Buitrago-Molina, S Marhenke, F Reisinger, A Saborowski, J Schütt, F Limbourg, C Könecke, A Schreder, A Michael, AC Misslitz, ME Healy, R Geffers, T Clavel, K Unger, M Finegold, A Weber, MP Manns, T Longerich, M Heikenwälder and **A Vogel**.

Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development.

Cancer Cell 2016, 8;30(2):308-23, IF 27,4

- 23) Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtländer T, Wacker F, Manns MP, Rodt T, **Vogel A**.

Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization.

Scandinavian Journal of Gastroenterology 2016, 22:1-9, IF 2,24

- 24) Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, **Vogel A**, Chiang DY
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Journal of Hepatology, 2016; 65(2):296-304. IF 12,48
- 25) G Folprecht, C Pericay, MP Saunders, A Thomas, R Lopez Lopez, JK Roh, V Chistyakov, T Höhler, JS Kim, RD Hofheinz, SP Ackland, D Swinson, M Kopp, D Udovitsa, M Hall, T Iveson, **A Vogel** JR Zalcborg.
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept infirst line treatment of patients with metastatic colorectal cancer – the AFFIRM study
Annals of Oncology, 2016, 27(7):1273-9, IF 11,85
- 26) H Toyoda, PBS Lai, J O'Beirne, CC Chong, S Berhane, H Reeves, D Manas, RP Fox, W Yeo, F Mo, A WH Chan, T Tada, M Iñarrairaegui, **A Vogel**, N Schweitzer, SL Chan, B Sangro, T Kumada, PJ Johnson.
Long-Term Impact of Liver Function on Curative Therapy for Hepatocellular Carcinoma: Application of the ALBI Grade
British Journal of Cancer, 2016, 29;114(7):744-750. PMID: 27022825 IF 5,57
-